CD274 and neoplasm: On the other hand, the relatively good efficacy of the anti-PD1/PD-L1 treatment in WAP-T tumor mice supports the idea that tumors expressing weak tumor antigen T-cell epitopes respond much better to immune checkpoint blockade therapies because re-establishment of an exhausted status of CTLs against these epitopes takes much longer.